Renal Denervation: Is It Ready for Prime Time?

被引：12
|
作者：
Lauder, Lucas [1 ]
Wolf, Milan A. [1 ]
Scholz, Sean S. [1 ]
Hohl, Mathias [1 ]
Mahfoud, Felix [1 ,2 ]
Boehm, Michael [1 ]
机构：
[1] Saarland Univ, Med Ctr, Univ Klinikum Saarlandes, Klin Innere Med 3,Kardiol,Angiol,Internist Intens, D-66421 Homburg, Germany
[2] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA
来源：
CURRENT CARDIOLOGY REPORTS | 2019年 / 21卷 / 08期
关键词：
Renal denervation; Device-based therapy; Hypertension; Interventional cardiology; TREATMENT-RESISTANT HYPERTENSION; BLOOD-PRESSURE; SYMPATHETIC DENERVATION; ATRIAL-FIBRILLATION; ARTERY DENERVATION; SYMPLICITY HTN-3; NERVOUS-SYSTEM; ADHERENCE; TRIAL; PATHOPHYSIOLOGY;
D O I：
10.1007/s11886-019-1164-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose of ReviewInterventional cardiology and in particular the field of renal denervation is subject to constant change. This review provides an up to date overview of renal denervation trials and an outlook on what to expect in the future.Recent FindingsAfter the sham-controlled SYMPLICITY HTN-3 trial dampened the euphoria following early renal denervation trials, the recently published results of the sham-controlled SPYRAL HTN and RADIANCE HTN trials provided proof-of-principle for the blood pressure-lowering efficacy of renal denervation. However, these studies underline the major issue of patients' non-adherence to antihypertensive medication as well as the need for reliable patient- and procedure-related predictors of response.SummaryThe second generation of sham-controlled renal denervation trials provided proof of principle for the blood pressure-lowering efficacy of RDN. However, larger trials have to assess long-term safety and efficacy.
引用
收藏
页数：8
相关论文
共 50 条
12345